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Abstract
Background: We assessed the validity of testing for antimicrobial susceptibility of clinical and mutant Neisseria
gonorrhoeae (GC) isolates by disk diffusion in comparison to agar dilution, and Etest® (bioMerieux, France),
respectively, for three third generation extended spectrum cephalosporins (ESC): ceftriaxone (CRO), cefixime (CFX),
and cefpodoxime (CPD).
Methods: One hundred and five clinical isolates and ten laboratory-mutants were tested following Clinical
Laboratory Standard Institute (CLSI) and manufacturer’s standards for each of the three methods. The measured
diameters by the disk diffusion method were tested for correlation with the MIC values by agar dilution. In addition,
comparisons with the Etest® were made. Categorical results for concordance, based on standard CLSI cutoffs,
between the disk diffusion and the other two methods, respectively, were tested using the Chi-square statistics.
Reproducibility was tested for CFX across a 6-month interval by repeated disk tests.
Results: Across all 115 specimens, the disk diffusion tests produced good categorical agreements, exhibiting
concordance of 93.1%, 92.1%, and 90.4% with agar dilution and 93.0%, 92.1%, and 90.4% with Etest®, for CRO, CFX,
and CPD, respectively. Pearson correlations between disk-diffusion diameters and agar dilution MIC’s were -0.59, -0.
67, and -0.81 for CRO, CFX, and CPD, respectively. The correlations between disk diffusion and Etest® were -0.58, -0.
73, and -0.49. Pearson correlation between the CFX disk readings over a 6-month interval was 91%.
Conclusions: Disk diffusion tests remain to be a useful, reliable and fast screening method for qualitative
antimicrobial susceptibility testing for ceftriaxone, cefixime, and cefpodoxime.
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Background
Neisseria gonorrhoeae (N. gonorrhoeae) is one of the
most common sexually transmitted pathogens. Its high
morbidity and associated medical and socio-economic
costs make it one of the major public health issues in
the U.S. and in the world. Approximately 300,000 cases
are reported to the CDC each year [1]. Because many
cases could be asymptomatic, a recent estimate indicates
that there may be more than 820,000 infected individ-
uals in the U.S [2]. Globally, many areas are experien-
cing significant rise in reported cases of gonorrhea.
According to the World Health Organization (WHO), in
2008 there were 106 million new cases of gonorrhea
worldwide [3].
CDC currently recommends that for uncomplicated
genital, rectal, and pharyngeal gonorrhea, a combination
of two drugs should be used; specifically, ceftriaxone
250 mg is administered intramuscularly (IM) in a single
dose, plus azithromycin 1 g orally in a single dose. When
ceftriaxone is not available, cefixime 400 mg orally in a
single dose is recommended to replace ceftriaxone in
combination with 1 g oral azithromycin [4, 5]. Treat-
ment guidelines also recommend individuals with
pharyngeal infections return for medical consultation
1 week post therapy to ensure success of therapy.
It is not clear whether combining two antimicrobials
with different mechanisms of action (e.g., ceftriaxone
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plus azithromycin) can delay the rise of isolates that are
resistant to the extended spectrum cephalosporins (ESC)
[6]. A recent report from Canada showed a significant
decline in decreased susceptibility to cephalosporins but
at the same time increased azithromycin resistance [7].
Despite the use of dual drug therapy, both CDC and
the WHO have warned that gonorrhea will soon become
more difficult to treat. This is because gonococcus is
well known for its ability to develop antimicrobial resist-
ance against first-line therapies within a short duration
of a drug’s introduction [8–11].
Until new drugs for treating gonorrhea are discovered,
there is urgent need for public health professionals to
closely monitor antimicrobial susceptibility of gonococci.
Quick identification of isolates that potentially possess
reduced susceptibility to cephalosporins is critical to
controlling the spread of drug-resistant gonococcal or-
ganisms. The recent emergence of isolates with reduced
antibiotic susceptibility across the country has further
alerted physicians and epidemiologists to the urgent
need to closely monitor such activities [10].
Three common tests are routinely used by laboratories
to determine the antimicrobial susceptibility of N. gonor-
rhoeae. The agar dilution test is the gold standard and is
used mostly by reference laboratories. We reported re-
cently that the Etest® (bioMerieux, France) is suitable to
serve as an alternative test [12]. Both agar dilution and
Etest methods report an MIC value which can be easily
used by physicians or epidemiologists to determine
treatment options. These two tests are appropriate for
finding organisms with increased MIC values. While
these tests are our first choice, they are not routinely
used by all laboratories.
A third test, the disk diffusion test, is more com-
monly used by microbiological laboratories and hospi-
tals world-wide to determine the antimicrobial
susceptibility of many organisms against wide-
spectrum antibiotics [9, 12–15]. The test is simple
and widely accepted by many laboratories. Its use,
however, is not without limitations. Disk diffusion test
results are observed as a diameter of inhibition-zone.
The diameter is relatively imprecise and often cannot
convert to a MIC value, but rather provides a cat-
egorical classification of susceptible, intermediate, or
resistant phenotypes [10]. For the treatment of gono-
cocci with cephalosporins, only susceptible and non-
susceptible categories are accepted for classifications
[13, 14, 16].
In the past 20 years, the number of laboratories using
the disk diffusion method for N. gonorrhoeae antimicro-
bial susceptibility testing has declined. In 1989, 86% of
public health laboratories surveyed used the disk diffu-
sion method [17]. In a study performed in New York in
2000, approximately 37.4% of laboratories used disk
diffusion [18]; in a 2012 study [19], 47% of laboratories
were utilizing disk diffusion tests for N. gonorrhoeae anti-
microbial susceptibility. Thus the disk diffusion method
remains the choice of many reference and regional labora-
tories and hospitals to survey gonococcal drug susceptibil-
ity. However, without sufficient clinically ESC resistant
isolates, it is not clear whether the disk diffusion method
can reliably detect future ESC resistance.
In this report, we compared the disk diffusion method
with the current gold standard agar dilution and a po-
tential alternative Etest method. We analyzed the suit-
ability and reliability of disk diffusion to monitor
susceptibility of N. gonorrhoeae isolates of the most
commonly used cephalosporins (ceftriaxone and cefix-
ime). In addition, we included 10 laboratory generated
mutants with raised MIC level against these common
ESCs to simulate non-susceptible isolates. Cefpodoxime
was also included in this study because it was used in
selecting laboratory generated mutants.
Methods
N. gonorrhoeae isolates
One hundred and five confirmed N. gonorrhoeae isolates
from various locations in the US, including Gonococcal
Isolate Surveillance Project (GISP) isolates and reference
strains, were used. In addition, 10 specimens of
laboratory-derived mutants that are non-susceptible to
cefpodoxime were selected. All 115 isolates were used in
all three tests. All isolates were confirmed by passage
and selection using the modified Thayer-Martin Medium
(Scientific Resource Program [SRP], CDC).
Mutation generation
The laboratory generated mutations were selected for
increased cephalosporin MICs by exposing parent
strains SPN284 or GC3502 to elevated concentrations
of cefpodoxime (3.0 ug/ml or 4.5 ug/ml) [20]. The
specific concentrations of cefpodoxime were included
in enriched GC agar base medium plates and 2-
4x1011 CFU of parent strain were inoculated. The
resulting colonies were subcultured and maintained
on GC agar base medium supplemented with 1% Iso-
VitaleX TM [Sigma-Aldrich, MO].
Antimicrobial susceptibility testing
Agar dilution tests and disk diffusion tests (BD BBL
Sensi-Disc, Becton, Dickinson and Company, MD,
U.S.A.) were performed by using the GC agar base
medium supplemented with 1% IsoVitaleX TM. Both
tests were performed according to the Clinical and La-
boratory Standards Institute (CLSI) agar dilution or disk
diffusion methods [21, 22]. The Etests were performed
according to the manufacturer’s recommendations (bio-
Merieux, France). Disk diffusion tests and Etests were
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performed at the same time while agar dilution tests
were performed by itself due to the complexity nature of
the test. Tests were prepared by suspending colonies of
N. gonorrhoeae from an overnight culture of Chocolate
II agar (Scientific Resources Program, SRP, CDC) into
Muller Hinton Broth (Difco Laboratories, MI) and ad-
justed to an optical density (BioMate3, Thermo-Fisher
Scientific) equal to that of a 0.5 McFarland standard.
The organisms were evenly spread on the surface of a
10x150 mm GC base agar plate using a cotton swab and
allowed to dry for about 10 min before the disks were
applied to the plate and duplicated plates were per-
formed. For the agar dilution method, a dilution of the
suspension approximately 104 CFU per spot was inocu-
lated within 15 min of preparation onto the GC base
agar surface with a Steers inoculator. The plates were in-
cubated at 35 °C in 5% CO2 for 20–24 h. The minimum
inhibitory concentrations (MICs) were interpreted by
reading growth inhibition (agar dilution) or the diameter
of the inhibition zone measured using a ruler (disk diffu-
sion). When replicates have different values, we report
the test value which has smaller diameter or larger MIC.
A panel of 7 quality control organisms: N. gonorrhoreae
ATCC 49226, F28, P681E, CDC10328, CDC10329,
SPJ15, and SPL4 were included in each assay for valid-
ation [23]. The disk diffusion and Etest methods were
performed simultaneously [12]. The Agar dilution was
performed according to CLIA specified guidelines.
Statistical analyses
Results between the disk diffusion, the agar dilution, and
Etest can be compared and quantified using the CLSI
cutoffs and categorical levels specified. Both agar dilu-
tion and Etest report MICs (μg/ml) which represent a
continuous metric of per-unit concentrations. Disk
diffusion provides an inhibition zone diameter which is
also a continuous metric but in mm of distance. Accord-
ingly, statistical comparisons between the MIC concen-
trations and the continuous metric diameter were
performed using simple correlation and linear regression
(Statistical Analysis System, Version 9.4). For all three
tests, there exist CLSI standard cutoff values [18] to de-
fine susceptibility and non-susceptibility of the ESC
spectrum antibiotics based on whether a particular test
result is above, equal to, or below the cutoff. Hence the
tests can be compared as a categorical outcome: suscep-
tible (S) or non- susceptible (nS). Simple 2x2 tables and
proportions concordant or not, between the pairwise test
comparisons, are provided (Table 1). The specific thresh-
old (cutoff ) values for each test and drug are included in
the table. To test for reproducibility, the disk diffusion
test of cefixime was repeated at multiple time points
over a 6-month period.
Results
The MICs measured by the agar dilution test and
the diameter (mm, inhibition zone) of the disk diffu-
sion test exhibit strong linear relationships for all
three antibiotics. The Pearson’s correlations between
disk diffusion and agar dilution test were -0.59,
-0.67, and -0.81 (p < 0.0001), respectively, for ceftri-
axone, cefixime, and cefpodoxime (Fig. 1a, b, c). Pre-
viously, the Etest was shown to perform comparably
to the agar dilution test [12]. When disk diffusion
was compared with Etest method, similar results
were obtained. The correlations between disk diffu-
sion and Etest for the three cephalosporins were
-0.58, -0.73, and -0.49, respectively. These results in-
clude all 115 pairs of tests, including clinical and
mutant specimens, to insure no artificial range
Table 1 Categorical Comparisons of the Susceptibility Testing Results of Disk Diffusion with Agar Dilution
Disk diffusion, zone diameter Agar dilution, MIC
Susceptible Non-Susceptible
Ceftriaxone (CRO) <=0.25 ug/ml >0.25 ug/ml Totals
Susceptible > = 35 mm 97 (84.4%) 0 (0.00%) 97 (84.4%)
Non- Susceptible <35 mm 8 (7.0%) 10 (8.7%) 18 (15.6%)
Totals 105 (91.3%) 10 (8.7%) 115 (100.0%)
Cefixime (CFX) <=0.25 ug/ml >0.25 ug/ml Totals
Susceptible > = 31 mm 94 (81.7%) 0 (0.0%) 94 (81.7%)
Non-Susceptible <31 mm 9 (7.8%) 12 (10.4%) 21 (18.3%)
Totals 103 (89.6%) 12 (10.4%) 115 (100.0%)
Cefpodoxime (CPD) <=0.5 μg/ml >0.5 μg/ml Totals
Susceptible > = 29 mm 58 (50.4%) 7 (6.1%) 65 (56.5%)
Non-Susceptible <29 mm 4 (3.5%) 46 (40.0%) 50 (43.5%)
Totals 62 (53.9%) 53 (46.1%) 115 (100.0%)
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limitations on the correlations. The disk diffusion re-
sults agreed well with both tests across the full
range of current clinical and potentially less suscep-
tible strains for all three antibiotics.
The concordance of disk diffusion to agar dilution of
the categorical results were 93.0%, 92.1%, and 90.4% for
ceftriaxone, cefixime, and cefpodoxime, respectively
(Table 1). For disk diffusion and Etest, respective
concordance rates were 93.0%, 92.1%, and 90.4%,
respectively.
To test for reproducibility, the disk diffusion test of
cefixime was repeated for each specimen. When the re-
sults of paired tests were compared, a 91% correlation
(p < 0.0001) was observed (Fig. 2).
Discussion
In this report, we studied the suitability and reliability of
disk diffusion to monitor susceptibility of N. gonorrhoeae
isolates of the most commonly used third generation
cephalosporins (ceftriaxone and cefixime). The results
and conclusions is limited to the three ESCs we tested
and should not be extended without additional study to
other molecules such as azithromycins or quinolones.
We have demonstrated that the disk diffusion test had
good correlations and categorical concordance when
compared with current gold standard the agar dilution
method (Fig. 1, Table 1). Disk diffusion also exhibited
good reproducibility for cefixime (Fig. 2). This finding is
important because the disk diffusion test remains a com-
mon method used by many regional laboratories and
hospitals for detection of antimicrobial resistance, and
the threat of reduced gonococcal susceptibility to ex-
tended spectrum cephalosporin may be imminent [10,
11, 24].
At present, there are few reported clinical cases of
gonorrhea with isolates that demonstrate decreased ESC
susceptibility [25–27]. In this study, we selected ten
laboratory-generated mutants based on their signifi-
cantly reduced in vitro susceptibility to three cephalo-
sporins. These mutants also have non- susceptible
phenotypes to cefixime and ceftriaxone as tested by agar
dilution methods and Etest [12, 20] (Fig. 1). These high-
MIC mutants (MIC values: 2–8 ug) were used to simu-
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Fig. 1 Plot of disk-diffusion zone diameter (mm) against agar-dilution
minimum inhibition concentration (MIC, μg/ml), with CLSI threshold
cutoffs for susceptibility. A total of 115 isolates were tested. a. Ceftriaxon
(CRO), b. Cefixime (CFX), c. Cefpodoxime (CPD). x-axis: Agar-dilution
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Fig. 2 Plot of disk-diffusion zone diameter (mm) against itself at two
different points in time, with fitted line and 95% confidence band, for
CFX. x-axis: Disk-diffusion zone diameter, time A (mm). y-axis: Repeat
Disk-diffusion zone diameter, time B (mm)
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and test whether disk diffusion method could reliably
detect future clinical isolates that are resistant to ESCs.
All ten isolates showed good categorical agreement. This
observation is important because it suggests that disk
diffusion remains appropriate as a routine method to de-
tect isolates with non-susceptibility phenotype.
GC-base medium and appropriate supplements (such
as IsoVitaleX) are recommended by the CLSI for testing
antibiotic susceptibility of N. gonorrhoeae species [16,
22]. However, in some regions clinical laboratories rou-
tinely use Chocolate agar (e.g., Choc II) as testing
medium. It has been reported that testing using the
Chocolate agar generates results similar to those of GC
base. However, a small discrepancy may result in missing
isolates that fall into the potential non-susceptible cat-
egory or generate false positives. Liao et al. have ob-
served a 5.5% false resistance rate when chocolate agar
is used compared with GC-base [28]. Thus, it is advis-
able that all laboratories using GC-base medium when
performing tests of gonococcus.
According to the CLSI, the ESC antimicrobial suscep-
tibility testing results for N. gonorrhoeae are classified
into two categories, susceptible and non-susceptible;
intermediate and resistant categories are not designated
at this time [21, 22]. For cefixime and ceftriaxone, iso-
lates with MICs greater than 0.25 ug/ml (or > = 0.5 ug/
ml) are considered not susceptible to these drugs. For
epidemiological purposes the CDC sometimes classifies
isolates with cefixime MICs > = 0.25 ug/ml and ceftriax-
one MICs > = 0.125 ug/ml as isolates having reduced-
susceptibility and an increase in numbers of reduced
susceptibility is a warning sign for clinicians [4, 5, 8].
This type of assessment cannot be achieved using the
disk diffusion test because at this time breakpoints (in
mm) are not available. Regardless, the GC-disk diffusion
test appears appropriate for qualitative antibiotic suscep-
tibility testing for clinicians to determine and choose the
appropriate ESCs for treatment when no other testing
alternatives are available.
However, the disk diffusion test has additional limita-
tions that should be considered. Training and experience
are required both for performing and reading the results.
Further, the test is labor-intensive and has similar limita-
tions to other culture-based tests. Reading the disk diffu-
sion test can be subjective, human errors can affect the
outcome, and despite good categorical classifications, it
may have somewhat larger reproducibility variations
than the Etest or agar dilution test. In this study, the
same batch of disks was used throughout the experi-
ments and the Etest strips were from one lot. Although
different batches of agar plates were used, there is no
reason to suspect that this variation had a major impact
on results. In addition, one technician performed and
read all tests. Given the nature of reading zone
diameters and Etest strips, we might expect higher vari-
ability if results were read by multiple technicians.
Conclusion
For public health laboratories performing susceptibility
testing of N. gonorrhoeae for ceftriaxone, cefixime, and
cefpodoxime, disk diffusion test remains a viable method
which produces results comparable to the current gold
standard, agar dilution.
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